Lakeland PeptidesPeptide therapy, explained · Lakeland & Polk County, FL

Goal

Peptides for Sexual Health: What Lakeland Readers Should Know

Not reviewed by a licensed provider. Read our disclaimer

Last updated

Sexual health is a personal topic, and it is easy to be drawn in by bold claims online. This page explains which peptides are marketed for sexual health, what each one is actually approved for, and what to ask a provider. It is general information, not advice for your situation.

Overview

Low desire, arousal problems and erection problems are common. They can have many causes: medicines, hormone levels, heart and blood vessel health, diabetes, depression, stress, relationship issues and more. That is why a full medical check is usually the first step.

Only one peptide on this page, bremelanotide (PT-141), is FDA-approved for a sexual-health use, and only for one specific group of women.1 Oxytocin is FDA-approved, but as a hospital injection used around childbirth, not for sex.2 The others are unapproved or experimental.

Peptides also work differently from familiar medicines like sildenafil. PT-141 and melanotan II act on melanocortin receptors in the brain and skin. Kisspeptin acts on the hormone signals that control fertility. Oxytocin is a natural hormone involved in childbirth and bonding.

Peptides used for sexual health

  • PT-141 (bremelanotide) (FDA-approved). FDA approved it as Vyleesi on June 21, 2019.3 It is labeled for premenopausal women with acquired, generalized hypoactive sexual desire disorder (low desire that causes distress) that is not caused by another medical or mental health condition, relationship problems or a medicine. It is not approved for men, for women after menopause, or to enhance sexual performance.1 It is a self-injection under the skin before expected sexual activity.1
  • Melanotan II (very limited human data). A lab-made version of a skin-darkening hormone. It was tested in two tiny studies of men with erection problems in the late 1990s but was never approved.4 FDA called it an unapproved new drug in a 2007 warning letter to an online seller of “tanning” injections.5
  • Kisspeptin (some human trials). A natural hormone that starts the chain of signals controlling ovulation and sperm production. It is experimental and not FDA-approved.6 In 32 men with low desire, a single IV dose given in a lab changed brain responses and erection measures.7 It has also been studied to trigger egg maturation during IVF.8
  • Oxytocin (FDA-approved for labor only). The FDA-approved form is a hospital injection used to start or strengthen labor when medically needed and to control bleeding after birth.2 There is no FDA-approved nasal oxytocin product marketed in the U.S.9

Testosterone is a different kind of treatment. It is a steroid hormone, not a peptide, and it is FDA-approved only for men whose low levels come from a diagnosed medical condition.10 Our peptides vs. TRT/HRT guide compares them.

What to realistically expect

  • PT-141’s benefit is modest. In two large trials in premenopausal women, desire scores rose by about a third of a point on a scale of 1.2 to 6 more than with placebo, and distress fell a little more.11 The number of satisfying sexual encounters did not increase.11 Many women improved on placebo too.11 An independent re-analysis questioned how meaningful the benefit is.12
  • Evidence in men is thin. Studies of PT-141 in men are small and older, and it is not labeled for men.13
  • Kisspeptin is still a research tool. Its human studies are small and mostly single doses in a lab. When women with missed periods took it repeatedly, their bodies stopped responding as strongly.14 No trials of online kisspeptin products for home use were found.
  • Oxytocin sprays have not lived up to the hype. Large, pre-registered studies did not find that nasal oxytocin increases trust.15 In a trial of 30 women with sexual problems, nasal oxytocin worked no better than placebo.16
  • Melanotan II is sold for tanning, not treatment. Its two small trials were in erection problems, and no controlled trial supports tanning or skin-cancer protection claims.45

If a clinic promises a dramatic change in desire or performance, treat that as a warning sign.

Safety considerations

  • PT-141 side effects. In trials, 40% had nausea, worst after the first dose, and 18% stopped because of side effects. Flushing and headache were also common.1 Blood pressure rises for a short time after each dose, so it is not for people with uncontrolled high blood pressure or heart disease. It can cause dark patches on the face, gums or breasts that may not fade. It interacts with oral naltrexone and should be avoided in pregnancy.1
  • Melanotan II risks. Doctors have reported new or changing moles in people who used it.17 FDA’s safety list cites case reports of melanoma, a brain swelling syndrome (PRES), overstimulation of the nervous system and priapism, a painful erection that will not go away.6 These reports cannot prove that melanotan II caused them. Products sold online are unregulated, so their contents and strength are uncertain.
  • Melanotan II and kisspeptin compounding. FDA lists kisspeptin-10 among substances that may pose significant safety risks in pharmacy compounding, citing possible immune reactions, impurities and little safety data.6 For melanotan II, the compounding nomination was withdrawn, but FDA still lists its safety concerns. A law-firm summary reports that FDA’s advisory committee plans to consider melanotan II before the end of February 2027.18 As of November 13, 2026, FDA had not announced the outcome of that review. Check FDA’s advisory committee calendar for updates.
  • Oxytocin injection risks. The approved injection is used under close hospital monitoring because it can cause overly strong contractions, uterine rupture, fetal distress and water intoxication.2
  • Other medicines. Bring a full list of what you take, including any heart or blood pressure medicines.

Seek care right away for chest pain, a severe headache, an erection lasting more than four hours, or a new or changing mole.

Questions to ask a provider

  • What could be causing my symptoms, and what tests do you recommend first?
  • Am I in the group this medicine is FDA-approved for? If not, what evidence supports using it for me?
  • Is this the FDA-approved product or a compounded one? Which pharmacy makes it?
  • How will you check my blood pressure and heart health before and during treatment?
  • What side effects should I watch for, and how do I reach you?
  • What other options, including counseling or non-peptide medicines, should I consider?
  • What is the total cost, and what does it include?

Our guide to your first peptide consultation has more questions to bring.

Footnotes

  1. Cosette Pharmaceuticals. VYLEESI (bremelanotide injection): prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf ↩ ↩2 ↩3 ↩4 ↩5

  2. Par Health USA. PITOCIN (oxytocin injection, USP): prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e5a66fc-e507-497c-b5ce-44a8c95898ad ↩ ↩2 ↩3

  3. U.S. Food and Drug Administration. NDA 210557 approval letter: Vyleesi (bremelanotide). June 21, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf ↩

  4. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. https://pubmed.ncbi.nlm.nih.gov/9679884/ ↩ ↩2

  5. U.S. Food and Drug Administration. Notice of opportunity for hearing, proposal to debar: Edward Manookian (Melanocorp). 2016. https://www.fda.gov/regulatory-information/electronic-reading-room/notice-opportunity-hearing-nooh-manookian-edward-8516 ↩ ↩2

  6. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026. Accessed November 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks ↩ ↩2 ↩3

  7. Mills EG, Ertl N, Wall MB, et al. Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254313. https://doi.org/10.1001/jamanetworkopen.2022.54313 ↩

  8. Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100(9):3322-3331. https://doi.org/10.1210/jc.2015-2332 ↩

  9. U.S. Food and Drug Administration. Drugs@FDA data via openFDA (drugsfda endpoint). Data last updated November 12, 2026. https://api.fda.gov/drug/drugsfda.json ↩

  10. Ascend Therapeutics. AndroGel (testosterone gel) 1.62%: prescribing information. Revised July 2025. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4e8d29b-8707-4d47-e053-2a95a90aecee ↩

  11. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. https://doi.org/10.1097/AOG.0000000000003500 ↩ ↩2 ↩3

  12. Spielmans GI. Re-analyzing phase III bremelanotide trials for “hypoactive sexual desire disorder” in women. J Sex Res. 2021;58(9):1085-1105. https://doi.org/10.1080/00224499.2021.1885601 ↩

  13. Ramez M, Mostafa MM, Mohamed H, et al. Peptides for male sexual dysfunction: a systematic review of emerging evidence. J Sex Med. 2026;23(12):qdag338. https://doi.org/10.1093/jsxmed/qdag338 ↩

  14. Jayasena CN, Nijher GM, Chaudhri OB, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-4323. https://doi.org/10.1210/jc.2009-0406 ↩

  15. Kroll CF, Schruers KRJ, Viechtbauer W, et al. Absence of a meaningful effect of intranasal oxytocin on trusting behavior: a registered report with pooled equivalence testing. Cortex. 2026;198:208-233. https://doi.org/10.1016/j.cortex.2026.03.006 ↩

  16. Muin DA, Wolzt M, Marculescu R, et al. Effect of long-term intranasal oxytocin on sexual dysfunction in premenopausal and postmenopausal women: a randomized trial. Fertil Steril. 2015;104(3):715-723.e4. https://doi.org/10.1016/j.fertnstert.2015.06.010 ↩

  17. Cardones AR, Grichnik JM. Alpha-melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. 2009;145(4):441-444. https://doi.org/10.1001/archdermatol.2008.623 ↩

  18. McDermott Will & Schulte. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. July 27, 2026. https://www.mcdermottlaw.com/insights/bulk-list-bound-pcac-backs-majority-of-peptides-in-two-day-public-meeting/ ↩

Frequently asked questions

What is PT-141?

PT-141 is another name for bremelanotide, sold as Vyleesi. It is FDA-approved only for premenopausal women with a specific type of low sexual desire that causes distress and is not explained by another condition, a relationship problem or a medicine.

Is PT-141 approved for men?

No. Vyleesi is not approved for men, for women after menopause, or to enhance sexual performance. Evidence in men is limited to small, older studies.

How much does PT-141 help?

Modestly. In two large trials, desire scores rose a little more than with placebo, and many women on placebo also improved. The number of satisfying sexual encounters did not increase.

Is melanotan II safe?

It has never been FDA-approved. Doctors have published reports of new or changing moles, melanoma and painful prolonged erections in people who used it, although these reports cannot prove it caused them.

Do oxytocin nasal sprays improve sex or bonding?

The evidence is weak. Large repeat studies did not find that oxytocin increases trust, and in one trial in women with sexual problems it worked no better than placebo.

Questions? Talk to a licensed provider

See a free list of top rated clinics in Lakeland and Polk County, with their phone numbers and Google reviews. No one will call you.

Find a top rated provider
Find a top rated provider today